Envoy Medical Enhances Its Patent Portfolio
Envoy Medical, Inc. (NASDAQ: COCH), a leader in the field of advanced hearing solutions, is excited to announce that it has recently been awarded a patent for its innovative rechargeable system tailored for its implantable devices. This milestone further supports the company’s mission of improving the lives of those facing significant hearing loss through technologies that are fully implanted.
Advances in Implantable Battery Technology
On September 3rd, the United States Patent and Trademark Office granted Envoy Medical Patent No. 12,081,061, titled "Recharge System for Implantable Battery." This groundbreaking technology is designed to manage the thermal aspects involved in charging an energy storage device that is implanted. In essence, it controls the current supplied during charging to keep the device’s battery at a safe temperature. This development is essential to ensure the safe operation of implanted medical technologies.
CEO’s Commitment to Innovation
"We’re thrilled to add this patent to our growing portfolio, which reflects our dedication to advancing technology in hearing solutions," said Brent Lucas, CEO of Envoy Medical. He highlighted the significance of regulating battery temperatures during charging. This patent marks a key step in reducing risks for implanted medical devices, showcasing Envoy Medical's commitment to innovation and patient safety.
Introducing the Esteem Fully Implanted Hearing Device
Envoy Medical has developed the Esteem fully implanted active middle ear implant (FI-AMEI), which is the only FDA-approved device in its category for adults suffering from moderate to severe sensorineural hearing loss. This device offers continuous hearing 24/7 by utilizing the natural structure of the ear, and importantly, it remains completely invisible. Users don’t have to deal with external components or in-ear insertions, setting it apart from traditional hearing aids. Once turned on, the Esteem functions without requiring daily handling, resulting in a truly effortless hearing experience.
Acclaim Cochlear Implant: A New Frontier
Along with the Esteem FI-AMEI, Envoy Medical is at the forefront of creating the Acclaim Cochlear Implant, expected to be the first fully implanted cochlear implant. Unlike standard cochlear implants, this innovative device captures sound using the anatomy of the natural ear, removing the need for a microphone. This pioneering method directly addresses severe to profound sensorineural hearing loss and is designed for adults who have been positively evaluated by qualified medical professionals.
Looking Ahead: Company Insights and Investor Relations
Envoy Medical’s Acclaim CI has already made waves by receiving the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This acknowledgment came shortly after the initial prototype was developed, highlighting the innovative nature of this device.
As the company strives to bring more innovative hearing solutions to the market, it also maintains an open line of communication with its investors. For investment inquiries or more detailed information, you can contact CORE IR at 516-222-2560 or reach out via email at investorrelations@envoymedical.com.
Frequently Asked Questions
What is Envoy Medical mainly focused on?
Envoy Medical primarily focuses on developing fully implanted hearing devices to help individuals with significant hearing loss.
What does the newly awarded patent cover?
The patent pertains to a recharge system designed to maintain safe temperature levels during the battery charging process in implanted devices.
What is the Esteem FI-AMEI?
The Esteem FI-AMEI is a fully implanted hearing device that allows users to enjoy natural hearing without the need for any external components.
How is the Acclaim Cochlear Implant different from traditional cochlear implants?
It captures sound using the natural anatomy of the ear instead of relying on a microphone, thus creating a more integrated hearing experience.
How can investors find more information about Envoy Medical?
Investors can access information through the SEC's website or directly contact the investor relations department.
